Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hard to Treat Diseases
Hard to Treat Diseases HTDS clinical trial protocol for MMR Vaccine expected Q2 2009
April 15th, 2009
Hard to Treat Diseases (HTDS) www.htdsmedical.com Today after the market closed the company announced the clinical trial protocol for their MMR Vaccine is under preparation, and is expected to be approved by the end of the second quarter 2009. The MMR Vaccine is a mixture of three live attenuated viruses administered via injection for immunization against measles, mumps, and rubella (also called German measles). It is generally administered to children around the age of one year, with a second dose before starting school (i.e. age 4/5). Prior to the widespread use of a vaccine against measles, its incidence was so high that infection was felt to be...
Source: Vaccine Weekly (2009-04-15)
|
